Genetic susceptibility to increased bacterial translocation influences the response to biological therapy in patients with Crohn's disease. Issue 2 (1st February 2013)

• Record Type: Journal Article
• Authors: Gutiérrez, Ana; Scharl, Michael; Sempere, Laura; Holler, Ernst; Zapater, Pedro; Almenta, Isabel; González-Navajas, José M; Such, José; Wiest, Reiner; Rogler, Gerhard; Francés, Rubén
• Is Part Of: Gut. Volume 63:Issue 2(2014)
• Page Start: 272
• Page End: 280
• Publication Date: 2013-02-01
• Subjects: Crohn'S Disease -- Bacterial Translocation -- Ibd - Genetics -- Infliximab -- Immune Response; Gastroenterology -- Periodicals; 616.33
• DOI: 10.1136/gutjnl-2012-303557
• Languages: English
• ISSNs: 0017-5749

Abstract

Abstract : Objective: The aetiology of Crohn's disease (CD) has been related to nucleotide-binding oligomerisation domain containing 2 (NOD2) and ATG16L1 gene variants. The observation of bacterial DNA translocation in patients with CD led us to hypothesise that this process may be facilitated in patients with NOD2/ATG16L1-variant genotypes, affecting the efficacy of anti-tumour necrosis factor (TNF) therapies. Design: 179 patients with Crohn's disease were included. CD-related NOD2 and ATG16L1 variants were genotyped. Phagocytic and bactericidal activities were evaluated in blood neutrophils. Bacterial DNA, TNFα, IFNγ, IL-12p40, free serum infliximab/adalimumab levels and antidrug antibodies were measured. Results: Bacterial DNA was found in 44% of patients with active disease versus 23% of patients with remitting disease (p=0.01). A NOD2-variant or ATG16L1-variant genotype was associated with bacterial DNA presence (OR 4.8; 95% CI 1.1 to 13.2; p=0.001; and OR 2.4; 95% CI 1.4 to 4.7; p=0.01, respectively). This OR was 12.6 (95% CI 4.2 to 37.8; p=0.001) for patients with a double-variant genotype. Bacterial DNA was associated with disease activity (OR 2.6; 95% CI 1.3 to 5.4; p=0.005). Single and double-gene variants were not associated with disease activity (p=0.19). Patients with a NOD2-variant genotype showed decreased phagocytic and bactericidal activities in blood neutrophils, increased TNFα levels in response to bacterial DNA and decreased trough levels of free anti-TNFα. The proportion of patients on an intensified biological therapy was significantly higher in the NOD2-variant groups. Conclusions: Our results characterise a subgroup of patients with CD who may require a more aggressive therapy to reduce the extent of inflammation and the risk of relapse.